Aug 5 (Reuters) - Danish drugmaker Novo Nordisk
said on Tuesday it has filed 14 new lawsuits in the
United States to stop companies from selling unapproved versions
of semaglutide, the main ingredient in its popular weight loss
and diabetes drugs, Wegovy and Ozempic.